EQUILLIUM, INC. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
EQUILLIUM, INC. (EQ) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 15.54 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-13
- EQUILLIUM, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-06-30 was 15.54M shares, a 37.85% increase year-over-year.
- EQUILLIUM, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 14.39M shares, a 24.82% increase year-over-year.
- EQUILLIUM, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-09-30 was 12.64M shares, a 19.74% increase year-over-year.
- EQUILLIUM, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-06-30 was 11.28M shares, a 21.87% increase year-over-year.
- EQUILLIUM, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 11.78M shares, a 13.39% increase from fiscal 2024.
- EQUILLIUM, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 10.39M shares, a 23.73% increase from fiscal 2023.
- EQUILLIUM, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 8.40M shares, a 29.81% increase from fiscal 2022.
- EQUILLIUM, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 6.47M shares, a 21.75% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|
| 2026-06-30 | 15.54M shares 10-Q · filed 2026-08-13 | 15.54M shares 10-Q · filed 2026-08-13 | ||
| 2026-03-31 | 14.39M shares 10-Q · filed 2026-05-13 | |||
| 2025-12-31 | 11.78M shares 10-K · filed 2026-03-25 | |||
| 2025-09-30 | 12.64M shares 10-Q · filed 2025-11-13 | 12.64M shares 10-Q · filed 2025-11-13 | ||
| 2025-06-30 | 11.28M shares 10-Q · filed 2026-08-13 | 11.28M shares 10-Q · filed 2026-08-13 | ||
| 2025-03-31 | 11.53M shares 10-Q · filed 2026-05-13 | |||
| 2024-12-31 | 10.39M shares 10-K · filed 2026-03-25 | |||
| 2024-09-30 | 10.56M shares 10-Q · filed 2025-11-13 | 10.56M shares 10-Q · filed 2025-11-13 | ||
| 2024-06-30 | 9.25M shares 10-Q · filed 2025-08-14 | 10.55M shares 10-Q · filed 2025-08-14 | ||
| 2024-03-31 | 10.41M shares 10-Q · filed 2025-05-14 | |||
| 2023-12-31 | 8.40M shares 10-K · filed 2025-03-27 | |||
| 2023-09-30 | 8.53M shares 10-Q · filed 2024-11-13 | |||
| 2023-06-30 | 8.68M shares 10-Q · filed 2024-08-08 | 8.68M shares 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | 8.46M shares 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | 6.47M shares 10-K · filed 2024-03-25 | |||
| 2022-09-30 | 6.70M shares 10-Q · filed 2023-11-08 | |||
| 2022-06-30 | 6.67M shares 10-Q · filed 2023-08-09 | |||
| 2022-03-31 | 6.58M shares 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | 5.31M shares 10-K · filed 2023-03-23 | |||
| 2021-09-30 | 5.29M shares 10-Q · filed 2021-11-10 | 5.29M shares 10-Q · filed 2022-11-14 | ||
| 2021-06-30 | 5.21M shares 10-Q · filed 2021-08-10 | 5.21M shares 10-Q · filed 2022-08-15 | ||
| 2021-03-31 | 5.31M shares 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | 2.54M shares 10-K · filed 2022-03-23 | |||
| 2020-09-30 | 2.55M shares 10-Q · filed 2021-11-10 | 2.55M shares 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | 2.49M shares 10-Q · filed 2021-08-10 | 2.49M shares 10-Q · filed 2021-08-10 | ||
| 2020-03-31 | 2.09M shares 10-Q · filed 2021-05-13 | |||
| 2019-12-31 | 1.90M shares 10-K · filed 2021-03-24 | |||
| 2019-09-30 | 1.28M shares 10-Q · filed 2020-11-10 | 1.28M shares 10-Q · filed 2020-11-10 | ||
| 2019-06-30 | 1.20M shares 10-Q · filed 2020-08-12 | 1.20M shares 10-Q · filed 2020-08-12 | ||
| 2019-03-31 | 1.15M shares 10-Q · filed 2020-05-13 | |||
| 2018-12-31 | 420.48K shares 10-K · filed 2020-03-26 | |||
| 2018-09-30 | 434.28K shares 10-Q · filed 2018-11-15 | 434.28K shares 10-Q · filed 2018-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |